Login
$ANTX
$4.47 -$0.08 (1.76%) Live

$ANTX SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end

06 Nov 2026 Form 4: Eizen Joshua M, See Remarks

Sold 2,826 shares ($11.9K)

13 Oct 2026 Form 4: Marks Gilbert Lynn, Director

Received 2,283 shares as a grant or award

13 Oct 2026 Form 4: Martin Patricia A., Director

Received 389 shares as a grant or award

13 Oct 2026 Form 4: Aziz Kabeer, Director

Received 2,465 shares as a grant or award

16 Sep 2026 Form 4: Trenor Cameron C. Iii, Chief Medical Officer

Received 116,667 shares as a grant or award · Granted 233,333 Stock Option (right to by)

14 Sep 2026 S-8
11 Sep 2026 Form 4: Readnour Robin Shane, Director

Sold 1,108 shares ($6.67K)

08 Sep 2026 Form 4: Readnour Robin Shane, Director

Sold 6,100 shares ($37K) · Sold 10,019 shares ($60.3K)

04 Sep 2026 Form 4: Williams Sarah Joanne, Principal Accounting Officer

Sold 272 shares ($1.5K)

02 Sep 2026 Form 4: FitzPatrick Margaret M, Director

Bought 2,098 shares ($11.6K)

27 Aug 2026 Form 3: Trenor Cameron C. Iii, Chief Medical Officer

No securities owned

19 Aug 2026 Form 4: Readnour Robin Shane, Director

Sold 35,402 shares ($213K)

17 Aug 2026 144
14 Aug 2026 Form 4: Zakrzewski Joseph S, Director

Gave 405,880 shares as a gift

11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support